Best Practice & Research Clinical Haematology

Papers
(The median citation count of Best Practice & Research Clinical Haematology is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Contemporary and future strategies in polycythemia vera59
The role of randomized controlled trials, registries, observational databases in evaluating new interventions24
HLA typing: A review of methodologies and clinical impact on haematopoietic cell transplantation24
Asparaginase dosing for obese patients with acute lymphoblastic leukemia and factors that contribute to outcomes21
Coagulopathy in COVID-19 and anticoagulation clinical trials18
Endpoint selection and evaluation in hematology studies18
“The state of the science” of childhood, adolescent and young adult Non Hodgkin Lymphoma (NHL)17
What are the long-term complications of pediatric ALL treatments and how can they be mitigated? Perspectives on long-term consequences of curative treatment in childhood ALL17
Allogeneic “Off-the-Shelf” CAR T cells: Challenges and advances16
Reducing barriers of access and care related to hematopoietic cell transplantation and cellular therapy: The mission-driven role of the national marrow donor program15
Take a spin: Apheresis in the care of adult leukaemia patients14
The presentation of results from studies in clinical haematology14
Advances in CAR design14
Editorial Board14
Blood coagulation and cancer genes13
Diagnosis and management of post-transplant lymphoproliferative disease following solid organ transplantation in children, adolescents, and young adults13
Biopathology of childhood, adolescent and young adult non-Hodgkin lymphoma13
Creating a GMP cell processing program: A focus on quality and regulation13
Targeted cellular therapy for treatment of relapsed or refractory leukemia11
Accelerated and blast phase myeloproliferative neoplasms11
Cytogenomics of B-cell non-Hodgkin lymphomas: The “old” meets the “new”10
Vaccine-induced immune thrombotic thrombocytopenia10
Principles of cost-effectiveness studies and their use in haematology10
How can we improve response assessments in MDS? Strategies to improve response assessment in MDS treatment paradigms10
Cancer associated thrombosis in pediatric patients9
Applications and prospects of molecularly targeted drugs combined with CAR-T cell therapy to treat multiple myeloma9
What should be done and what should be avoided when comparing two treatments?9
The international cooperative Gaucher group (ICCG) Gaucher registry9
Editorial Board8
Dysregulation of Protein S in COVID-198
Clinical experience of CAR T cells for multiple myeloma8
Late effects and frontline treatment selection for children with non-Hodgkin lymphoma7
Addressing symptom burden in myeloproliferative neoplasms7
Prevention and treatment of COVID-19 in patients with benign and malignant blood disorders7
Is HLA-E with its receptors an immune checkpoint or an antigenic determinant in allo-HCT?7
Worldwide sources of data in haematology: Importance of clinician-biostatistician collaboration7
The role of registries in hematological disorders7
Human mesenchymal stem cell therapy: Potential advances for reducing cystic fibrosis infection and organ inflammation6
How predictive is the finding of clonal hematopoiesis for the development of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)?6
Hodgkin Lymphoma: A disease shaped by the tumor micro- and macroenvironment6
Anti-GM-CSF autoantibodies in myeloid leukemias6
The analysis of multiple outcomes, multiple variables and variables selection in hematopoietic cell transplantation studies6
Corrigendum to “Precision immunomodulation: Understanding and harnessing cytokine pathways to treat and prevent immune-related adverse events (irAEs)” [Best Pract Res Clin Haematol 38 2 2025]6
Handling missing covariate data in clinical studies in haematology6
What is the role of the bone marrow microenvironment in AML?5
Editorial Board / Aims & Scope5
Preface5
The current landscape: Allogeneic hematopoietic stem cell transplant for acute lymphoblastic leukemia5
Thrombosis and bleeding in hematological malignancy5
Cytokines in hematopoietic cell transplantation and related cellular therapies5
CAR assembly line: Taking CAR T-cell manufacturing to the next level5
Corrigendum to “Endpoint selection and evaluation in hematology studies” [Best Pract Res Clin Haematol 36 (2023) 101479]5
Challenges in anticoagulation for patients with brain tumors5
Advances in polycythemia vera and lessons for acute leukemia5
Recent progress in acute leukemia and myelodysplasia5
A reflection on Arnold Caplan, the father of MSC5
Therapeutic initiatives using mesenchymal stem cells and other novel cells in hematology4
The most frequent HLA alleles around the world: A fundamental synopsis4
What is relative survival and what is its role in haematology?4
Clinical experience of CAR T cell therapy in lymphomas4
Relevance of donor-specific HLA antibodies in hematopoietic cell transplantation4
Cytogenetics and genomics in CML and other myeloproliferative neoplasms4
Corrigendum to “Designing and conducting a clinical trial in blood and marrow transplantation” [Best Pract Res Clin Haematol 36 (2023) 101471]4
Since everyone has a donor, why are some eligible patients still not transplanted?3
When to use which molecular prognostic scoring system in the management of patients with MDS?3
Preface of special edition “Biostatistics in clinical haematology”3
Diagnosis and management of rare paediatric Non-Hodgkin lymphoma3
Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents3
Cytokine therapy of acute radiation syndrome3
The correlations among racial/ethnic groups, hypertriglyceridemia, thrombosis, and mortality in hospitalized patients with COVID-193
Considerations to comprehensive care for the older individual with myelofibrosis3
SARS-CoV-2 primary and breakthrough infections in patients with cancer: Implications for patient care3
Shape of the art: TCR-repertoire after allogeneic hematopoietic cell transplantation3
Mesenchymal stem cells in hematology: Therapeutic initiatives and future directions3
Editorial Board / Aims & Scope3
COVID-19 and antiphospholipid antibodies3
Measurable residual disease in patients undergoing allogeneic transplant for acute myeloid leukemia3
Donor lymphocyte infusion in Acute Myeloid Leukemia3
CARs for lymphoma3
Diagnosis and management of mature B-cell lymphomas in children, adolescents, and young adults3
Interfering with KIR and NKG2A immune checkpoint axes to unleash NK cell immunotherapy3
COVID-19: A hematological perspective2
Redox stress in COVID-19: Implications for hematologic disorders2
Consolidation chemotherapy in AML: Are we playing with a full deck of cards?2
Thromboprophylaxis of cancer patients undergoing systemic therapy in the ambulatory setting2
The Collaborative Biobank (CoBi): Donor and recipient samples & data to facilitate future research on hematopoietic cell transplantation2
Using real-world evidence in haematology2
Cytokines in transplantation tolerance2
Designing and conducting a clinical trial in blood and marrow transplantation2
Editorial Board / Aims & Scope2
Can venetoclax-based therapy replace 7+3 induction in fit older adults with AML?2
The best GVHD prophylaxis: Or at least progress towards finding it2
Research progress of targeted BCMA CAR-T therapy for relapsed/refractory multiple myeloma antigen-negative relapse2
Diagnosis and management of Hodgkin lymphoma in children, adolescents, and young adults2
Is there an optimal adjunct therapy to traditional cytotoxic induction?2
Germline predisposition to myeloid neoplasms: Characteristics and management of high versus variable penetrance disorders2
Transplantation algorithm for myelofibrosis in 2022 and beyond1
New targets for CAR T therapy in hematologic malignancies1
Editorial Board1
Measurable residual disease in acute lymphoblastic leukemia: How low is low enough?1
Adoptive cellular therapies in multiple myeloma1
Myeloproliferative neoplasms in adolescents and young adults1
The Australian Aplastic Anaemia and other Bone Marrow Failure Syndromes Registry1
Advancing MSC therapy: The next generation of potent mesenchymal stromal cells for systemic autoimmune rheumatic diseases1
Analyte heterogeneity analysis as a possible potency parameter for MSC1
Cytogenetics and genomics in pediatric acute lymphoblastic leukaemia1
The history of cytokines and growth factors development1
Minor histocompatibility antigens to predict, monitor or manipulate GvL and GvHD after allogeneic hematopoietic cell transplantation1
Allogeneic hematopoietic cell transplantation in acute myeloid leukemia1
Cytogenetics in haematology1
Effectiveness of allogeneic hematopoietic cell transplantation for older patients with acute myeloid leukemia1
HLA-DM and HLA-DO interplay for the peptide editing of HLA class II in healthy tissues and leukemia1
Has Ph-like ALL Superseded Ph+ ALL as the Least Favorable Subtype?1
Editorial Board1
How can we intervene to mitigate post-transplantation relapse in AML? Strategies to mitigate post-transplantation relapse in AML1
WHO, what, when, where, and why: New classification systems for acute myeloid leukemia and their impact on clinical practice1
Progress and challenges in the acute leukemia field1
Cytogenetics and genomics of acute myeloid leukemia1
Graft versus Leukemia in 20231
Immunopathogenic mechanisms and modulatory approaches to graft-versus-host disease prevention in acute myeloid leukaemia1
Natural born Killers: Harnessing NK cells to treat cancer1
Clinical experience of CAR T cells for B cell acute lymphoblastic leukemia1
Important factors improving outcome of young adults with acute lymphoblastic leukemia (ALL)1
0.033379793167114